 |
|
Azithromycin vs Cefuroxime Plus Erythromycin for Empirical Treatment of Community-Acquired Pneumonia in Hospitalized Patients
A Prospective, Randomized, Multicenter Trial
Emanuel N. Vergis, MD;
Amy Indorf, MD;
Thomas M. File, Jr, MD;
James Phillips, MD;
Joseph Bates, MD;
James Tan, MD;
George A. Sarosi, MD;
J. Thomas Grayston, MD;
James Summersgill, MD;
Victor L. Yu, MD
Arch Intern Med. 2000;160:1294-1300.
Objective To compare the efficacy and safety of azithromycin dihydrate monotherapy with those of a combination of cefuroxime axetil plus erythromycin as empirical therapy for community-acquired pneumonia in hospitalized patients.
Methods Patients were enrolled in a prospective, randomized, multicenter study. The standard therapy of cefuroxime plus erythromycin was consistent with the American Thoracic Society, Canadian Community-Acquired Pneumonia Consensus Group, and Infectious Disease Society of America consensus guidelines. The doses were intravenous azithromycin (500 mg once daily) followed by oral azithromycin (500 mg once daily), intravenous cefuroxime (750 mg every 8 hours), followed by oral cefuroxime axetil (500 mg twice daily), and erythromycin (500-1000 mg) intravenously or orally every 6 hours. Randomization was stratified by severity of illness and age. Patients who were immunosuppressed or residing in nursing homes were excluded.
Results Data from 145 patients (67 received azithromycin and 78 received cefuroxime plus erythromycin) were evaluable. Streptococcus pneumoniae and Haemophilus influenzae were isolated in 19% (28/145) and 13% (19/145), respectively. The atypical pathogens accounted for 33% (48/145) of the etiologic diagnoses; Legionella pneumophila, Chlamydia pneumoniae, and Mycoplasma pneumoniae were identified in 14% (20/145), 10% (15/145), and 9% (13/145), respectively. Clinical cure was achieved in 91% (61/67) of the patients in the azithromycin group and 91% (71/78) in the cefuroxime plus erythromycin group. Adverse events (intravenous catheter site reactions, gastrointestinal tract disturbances) were significantly more common in patients who received cefuroxime plus erythromycin (49% [30/78]) than in patients who received azithromycin (12% [8/67]) (P<.001).
Conclusions Treatment with azithromycin was as effective as cefuroxime plus erythromycin in the empirical management of community-acquired pneumonia in immunocompetent patients who were hospitalized. Azithromycin was well tolerated.
From the Infectious Disease Sections, Veterans Affairs Medical Center and University of Pittsburgh, Pittsburgh, Pa (Drs Vergis and Yu), and Summa Health System, Akron, and Northeastern Ohio Universities College of Medicine, Rootstown, Ohio (Drs Indorf, File, and Tan); Medical Service, John L. McClellan Memorial Veterans Affairs Medical Center, Little Rock, Ark (Drs Phillips and Bates); Medical Service, Veterans Affairs Medical Center, San Jose, and Stanford University Medical School, Stanford, Calif (Dr Sarosi); School of Public Health and Community Medicine, University of Washington, Seattle (Dr Grayston); and Infectious Disease Laboratory, University of Louisville School of Medicine, Louisville, Ky (Dr Summersgill).
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(9):1379-1380.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Development of Real-Time Multiplex Nucleic Acid Sequence-Based Amplification for Detection of Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella spp. in Respiratory Specimens
Loens et al.
J. Clin. Microbiol. 2008;46:185-191.
ABSTRACT
| FULL TEXT
Antibiotics for Bacteremic Pneumonia: Improved Outcomes With Macrolides but Not Fluoroquinolones
Metersky et al.
Chest 2007;131:466-473.
ABSTRACT
| FULL TEXT
A Cost-Minimization Analysis Comparing Azithromycin-Based and Levofloxacin-Based Protocols for the Treatment of Patients Hospitalized With Community-Acquired Pneumonia: Results From the CAP-IN Trial
Samsa et al.
Chest 2005;128:3246-3254.
ABSTRACT
| FULL TEXT
Macrolides in Community-Acquired Pneumonia: Does the Bell Toll for Thee?
Granowitz and Brown
Chest 2005;128:1089-1093.
FULL TEXT
Acute Hemorrhagic Pericarditis in a Child with Pneumonia Due to Chlamydophila pneumoniae
Tenenbaum et al.
J. Clin. Microbiol. 2005;43:520-522.
ABSTRACT
| FULL TEXT
Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia
File et al.
Chest 2004;125:1888-1901.
ABSTRACT
| FULL TEXT
Steady-State Plasma and Bronchopulmonary Concentrations of Intravenous Levofloxacin and Azithromycin in Healthy Adults
Rodvold et al.
Antimicrob. Agents Chemother. 2003;47:2450-2457.
ABSTRACT
| FULL TEXT
Azithromycin Monotherapy for Patients Hospitalized With Community-Acquired Pneumonia: A 31/2-Year Experience From a Veterans Affairs Hospital
Feldman et al.
Arch Intern Med 2003;163:1718-1726.
ABSTRACT
| FULL TEXT
Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers
Chiu et al.
J Antimicrob Chemother 2002;50:1075-1079.
ABSTRACT
| FULL TEXT
Cost-Effectiveness of IV-to-Oral Switch Therapy: Azithromycin vs Cefuroxime With or Without Erythromycin for the Treatment of Community-Acquired Pneumonia
Paladino et al.
Chest 2002;122:1271-1279.
ABSTRACT
| FULL TEXT
Fluoroquinolones for Respiratory Infections : Too Valuable To Overuse
Williams
Chest 2001;120:1771-1775.
FULL TEXT
Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections
Contopoulos-Ioannidis et al.
J Antimicrob Chemother 2001;48:691-703.
ABSTRACT
| FULL TEXT
Guidelines for the Management of Adults with Community-acquired Pneumonia . Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention
Niederman et al.
Am. J. Respir. Crit. Care Med. 2001;163:1730-1754.
FULL TEXT
Empiric Antibiotic Therapy and Mortality Among Medicare Pneumonia Inpatients in 10 Western States : 1993, 1995, and 1997
Houck et al.
Chest 2001;119:1420-1426.
ABSTRACT
| FULL TEXT
Fatal Pneumococcal Pneumonia Attributed to Macrolide Resistance and Azithromycin Monotherapy
Waterer et al.
Chest 2000;118:1839-1840.
FULL TEXT
Azithromycin Equals Cefuroxime-Erythromycin for Inpatient CAP
JWatch Infect. Diseases 2000;2000:14-14.
FULL TEXT
|
